Insulet slides after updated Class I recall record for Omnipod 5 pods draws fresh attention

Insulet Corporation (PODD) is down 9.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to renewed investor focus on a Class I recall involving certain Omnipod 5 pods, after the U.S. medical-device recall record showed an update dated May 26, 2026. Even when an issue is previously disclosed, a fresh regulatory update can spark selling due to concerns about replacement costs, reputational impact, and potential supply disruption.

Details:

The U.S. regulator’s recall database lists a Class I recall for Omnipod 5 pods tied to potential under-delivery of insulin, describing serious potential health outcomes if the issue occurs.

The recall entry indicates nationwide distribution and shows more than 1.2 million units listed in commerce, which can heighten concerns about the operational scope of corrective actions.

A regulator bulletin in late April noted that the communication was updated with newly affected lots and confirmed the issue as a Class I recall, which is the most serious classification.

Earlier this month, the company reported Q1 2026 results and raised full-year revenue guidance, suggesting today’s drop is more likely recall-driven than earnings-driven.

Sources:

U.S. Food and Drug Administration, FDA MedWatch, Business Wire

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$PODD Insider Trading Activity

$PODD insiders have traded $PODD stock on the open market 4 times in the past 6 months. Of those trades, 3 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $PODD stock by insiders over the last 6 months:

ASHLEY MCEVOY (President and CEO) purchased 4,300 shares for an estimated $1,029,205
WAYNE A.I. FREDERICK sold 1,851 shares for an estimated $542,509
MICHAEL R MINOGUE purchased 2,030 shares for an estimated $499,846
TIMOTHY C. STONESIFER purchased 962 shares for an estimated $299,884

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$PODD Hedge Fund Activity

We have seen 404 institutional investors add shares of $PODD stock to their portfolio, and 454 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL RESEARCH GLOBAL INVESTORS removed 2,739,416 shares (-62.1%) from their portfolio in Q1 2026, for an estimated $574,839,053
FMR LLC removed 2,350,642 shares (-37.2%) from their portfolio in Q1 2026, for an estimated $493,258,717
AQR CAPITAL MANAGEMENT LLC added 1,139,609 shares (+248.2%) to their portfolio in Q1 2026, for an estimated $239,135,552
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 1,011,369 shares (+462.7%) to their portfolio in Q1 2026, for an estimated $212,225,670
JUPITER ASSET MANAGEMENT LTD added 475,438 shares (+202.8%) to their portfolio in Q1 2026, for an estimated $99,765,909
SOLEUS CAPITAL MANAGEMENT, L.P. added 412,500 shares (+275.0%) to their portfolio in Q1 2026, for an estimated $86,559,000
TWO SIGMA INVESTMENTS, LP added 395,627 shares (+107.9%) to their portfolio in Q1 2026, for an estimated $83,018,369

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$PODD Congressional Stock Trading

Members of Congress have traded $PODD stock 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $PODD stock by members of Congress over the last 6 months:

SENATOR TINA SMITH has traded it 2 times. They made 0 purchases and 2 sales worth up to $500,000 on 05/07, 04/29.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$PODD Analyst Ratings

Wall Street analysts have issued reports on $PODD in the last several months. We have seen 3 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

Here are some recent analyst ratings:

William Blair issued a "Outperform" rating on 05/20/2026
JP Morgan issued a "Overweight" rating on 05/07/2026
Barclays issued a "Underweight" rating on 01/12/2026
Truist Securities issued a "Buy" rating on 12/18/2025

To track analyst ratings and price targets for $PODD, check out Quiver Quantitative's $PODD forecast page.

$PODD Price Targets

Multiple analysts have issued price targets for $PODD recently. We have seen 17 analysts offer price targets for $PODD in the last 6 months, with a median target of $250.0.

Here are some recent targets:

Travis Steed from B of A Securities set a target price of $208.0 on 05/18/2026
Matt Miksic from Barclays set a target price of $198.0 on 05/08/2026
Lee Hambright from Bernstein set a target price of $200.0 on 05/07/2026
Suraj Kalia from Oppenheimer set a target price of $210.0 on 05/07/2026
Richard Newitter from Truist Securities set a target price of $250.0 on 05/07/2026
Daniel Markowitz from Evercore ISI Group set a target price of $200.0 on 05/07/2026
Lawrence Biegelsen from Wells Fargo set a target price of $255.0 on 05/07/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.